Zobrazeno 1 - 10
of 73
pro vyhledávání: '"H.-J. Spaar"'
Autor:
P. Gutjahr, M. Schwenger, H. J. Spaar, J. Michaelis, D. Niethammer, H. Jürgens, J. Kühl, R. Ludwig, J. Kutzner, D. Schmidt, R. Hohenfellner
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 115:248-253
Between 1980 and 1988, in a prospective study of 373 children with Wilms' tumour throughout the Federal Republic of Germany, the results of various pre- and postoperative treatment schedules were analysed. There were 184 boys and 189 girls, mean age
Publikováno v:
Klinische Pädiatrie. 219:134-138
BACKGROUND Daunorubicin (DNR) is one of the most important drugs in treatment of acute lymphoblastic leukemia (ALL). Prolonged infusions of anthracyclines are less cardiotoxic but it has not been investigated whether the in vivo leukemic cell kill is
Autor:
U. Graubner, M L den Boer, H. J. Spaar, D. Harms, K.M. Kazemier, D. Körholz, Rob Pieters, U. Göbel, Gritta Janka-Schaub, Anjo J.P. Veerman, N. Jorch, Gertjan J.L. Kaspers, R.J. Haas, E. R. Van Wering, W.A. Kamps, A. van der Does-van den Berg
Publikováno v:
Den Boer, M L, Harms, D O, Pieters, R, Kazemier, K M, Göbel, U, Körholz, D, Graubner, U, Haas, R J, Jorch, N, Spaar, H J, Kaspers, G J L, Kamps, W A, Van Der Does-Van Den Berg, A, Van Wering, E R, Veerman, A J P & Janka-Schaub, G E 2003, ' Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia ', Journal of Clinical Oncology, vol. 21, no. 17, pp. 3262-3268 . https://doi.org/10.1200/JCO.2003.11.031
Journal of Clinical Oncology, 21(17), 3262-3268. American Society of Clinical Oncology
Journal of Clinical Oncology, 21(17), 3262-3268. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 21(17), 3262-3268. American Society of Clinical Oncology
Journal of Clinical Oncology, 21(17), 3262-3268. AMER SOC CLINICAL ONCOLOGY
Purpose : To confirm the prognostic value of a drug resistance profile combining prednisolone, vincristine, and L-asparaginase (PVA) cytotoxicity in an independent group of children with acute lymphoblastic leukemia (ALL) treated with a different pro
Autor:
Günter Henze, Hartmut Kabisch, Martin Zimmermann, Helmut Gadner, Hermann J, Astrid Gnekow, Frank Berthold, Dieter Körholz, P. Imbach, J. Ritter, H.-J. Spaar, U. Creutzig, Dirk Reinhardt, Charlotte M. Niemeyer, A. Reiter, Heribert Jürgens, Ulrike Graubner, Gudrun Fleischhack, Joachim Boos
Publikováno v:
Klinische Pädiatrie. 213:175-185
Background In the multicenter trial AML-BFM 93 daunorubicin or idarubicin was randomly applied in all patients during induction in combination with cytarabine and etoposide. After induction all patients were stratified to the standard or high risk gr
Autor:
D. Harms, H. J. Spaar, Heribert Jürgens, Ulrich Göbel, K. Waag, Gabriele Calaminus, Dominik Schneider, W. Sternschulte
Publikováno v:
Journal of Clinical Oncology. 19:1943-1950
PURPOSE: To evaluate a multimodal approach including surgery and cisplatinum chemotherapy for treatment of children with malignant sacrococcygeal germ cell tumors (GCT) and to compare adjuvant and neoadjuvant strategies in advanced tumors. PATIENTS A
Autor:
Gritta Janka, U zur Stadt, Martin Schrappe, S. Völpel, Hartmut Kabisch, P. Gutjahr, D. Harms, S. Schlüter, H.-J. Spaar, Norbert Jorch, W. Nürnberger
Publikováno v:
Klinische Pädiatrie. 212:169-173
The detection of minimal residual disease (MRD) is a major prognostic factor for treatment in acute lymphoblastic leukemia (ALL) of childhood. Several groups showed the predictive value of MRD after 5 weeks of chemotherapy (at the end of induction th
Autor:
Norbert Graf, U. Creutzig, P. Bucsky, M. Domula, Werner Havers, K. Kabisch, A. J. P. Veerman, Rob Pieters, Ch. M. Zwaan, Norbert Jorch, Ulrich Göbel, Gertjan J.L. Kaspers, Jörg Ritter, H.-J. Spaar, Marianne G. Rots
Publikováno v:
Klinische Padiatrie, 211(4), 239-244. Georg Thieme Verlag
Kaspers, G J L, Zwaan, C M, Veerman, A J P, Rots, M G, Pieters, R, Bucsky, P, Domula, M, Göbel, U, Graf, N, Havers, W, Jorch, N, Kabisch, K, Spaar, H J, Ritter, J & Creutzig, U 1999, ' Cellular drug resistance in acute myeloid leukemia : Literature review and preliminary analysis of an ongoing collaborative study ', Klinische Padiatrie, vol. 211, no. 4, pp. 239-244 . https://doi.org/10.1055/s-2008-1043795
ResearcherID
Klinische Padiatrie, 211, 239-244. Georg Thieme Verlag
Kaspers, G J L, Zwaan, C M, Veerman, A J P, Rots, M G, Pieters, R, Bucsky, P, Domula, M, Göbel, U, Graf, N, Havers, W, Jorch, N, Kabisch, K, Spaar, H J, Ritter, J & Creutzig, U 1999, ' Cellular drug resistance in acute myeloid leukemia : Literature review and preliminary analysis of an ongoing collaborative study ', Klinische Padiatrie, vol. 211, no. 4, pp. 239-244 . https://doi.org/10.1055/s-2008-1043795
ResearcherID
Klinische Padiatrie, 211, 239-244. Georg Thieme Verlag
Cellular drug resistance is one of the main causes of the frequent ultimate failure of chemotherapy in childhood acute myeloid leukemia (AML). We here summarize the results of a literature review on in vitro drug resistance in childhood AML, focusing
Autor:
Martin Schrappe, Joachim Boos, Bernd H. Belohradsky, H.-J. Spaar, Wolfgang Dörffel, Charlotte M. Niemeyer, Ursula Creutzig, Max Lakomek, Ulrike Graubner
Publikováno v:
Klinische Pädiatrie. 211:347-352
Infections in disease- and/or chemotherapy-related neutropenia are major, often emergency-type problems in the treatment of pediatric oncology patients and explain the ongoing discussion about antiinfectious prophylaxis. The different aspects of prop
Publikováno v:
Acta Neurochirurgica. 139:961-969
Three cases of primary rhabdoid tumour of the CNS (RT-CNS) are presented. In case 1 a hemispheric tumour developed in a 10.5 months old girl, who survived for 6 months after incomplete resection, radio- and polychemotherapy. Case 2 was a 4 years and
Autor:
U. Graubner, R. J. Haas, U. Goebel, P. Gutjahr, G. E. Janka-Schaub, Dieter Harms, H. Juergens, H. J. Spaar, K. Winkler
Publikováno v:
European Journal of Pediatrics. 155:640-648
A frequent change of drug combinations may circumvent drug resistance in the treatment of patients with acute lymphoblastic leukaemia (ALL). In study COALL 85/89 201 children with high-risk ALL were randomized to receive over a period of 8 months rot